Results 251 to 260 of about 106,627 (314)

Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable‐Intermediate and High‐Risk Prostate Cancer

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Standard treatment for unfavorable‐intermediate and high‐risk prostate cancer involves androgen deprivation therapy (ADT) in combination with pelvic conventional fractionation (CF) external beam radiotherapy (EBRT) and a CF‐EBRT or brachytherapy boost to the prostate.
Andre Gouveia   +18 more
wiley   +1 more source

Impact of Concomitant Hormone Therapy on the Diagnostic Performance of 18F‐Piflufolastat PET/CT in Prostate Cancer Patients: A Sub‐Group Analysis of OSPREY Cohort B

open access: yesThe Prostate, EarlyView.
ABSTRACT Background This study investigates the impact of hormone therapy (HT) on the diagnostic performance of 18F‐piflufolastat PET/CT in OSPREY (NCT02981368) cohort B patients with recurrent or metastatic prostate cancer. Methods 18F‐piflufolastat PET/CT was evaluated in OSPREY cohort B patients (n = 117 men) with elevated prostate‐specific antigen (
Lawrence Saperstein   +9 more
wiley   +1 more source

Unveiling the potential of emerging microRNA panels as diagnostic biomarkers for prostate cancer: A review

open access: yesUroPrecision, EarlyView.
Abstract Prostate cancer (PCa) is a multifaceted disease that envelops 1.41 million new cases globally. It is the second most common cancer reported in men. Its heterogeneity and indolent growth, coupled with incompetent early screening methods such as serum prostate‐specific antigen level estimations and digital rectal examinations, contribute to its ...
Anveshika Manoj   +2 more
wiley   +1 more source

Steroid receptors and coregulators: Dissemination of sex differences and emerging technologies. [PDF]

open access: yesJ Biol Chem
Pauss SN   +6 more
europepmc   +1 more source

Metastatic intrigue: Penile involvement in prostate cancer with neuroendocrine differentiation—A case report

open access: yesUroPrecision, EarlyView.
Abstract Background Neuroendocrine carcinoma of the prostate is a rare tumor subtype found in the spectrum of prostate cancer, and is more difficult to detect, due to the low prostate‐specific antigen values associated with it. A high degree of suspicion is hence needed to arrive at the diagnosis in such cases.
Uttam Kumar Mete   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy